Cargando…
Novel ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV2
SARS-CoV2, the etiologic agent of COVID-19, uses ACE2 as a cell entry receptor. Soluble ACE2 has been shown to have neutralizing antiviral activity but has a short half-life and no active transport mechanism from the circulation into the alveolar spaces of the lung. To overcome this, we constructed...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cold Spring Harbor Laboratory
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310620/ https://www.ncbi.nlm.nih.gov/pubmed/32587964 http://dx.doi.org/10.1101/2020.06.15.152157 |